SUSTAINABLE DEVELOPMENT
Innovate. Sustain. Transform.
Save up to 30% on top Physical Sciences & Engineering titles!
Genomic and Precision Medicine
Oncology
- 3rd Edition - April 9, 2022
- Editors: Geoffrey S. Ginsburg, Huntington F Willard, John Strickler, Matthew Stuart McKinney
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 0 0 6 8 4 - 9
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 0 0 6 5 3 - 5
Genomic and Precision Medicine: Oncology, Third Edition focuses on the applications of genome discovery as research points to personalized cancer therapies. Each chapter is organi… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteGenomic and Precision Medicine: Oncology, Third Edition focuses on the applications of genome discovery as research points to personalized cancer therapies. Each chapter is organized to cover the application of genomics and personalized medicine tools and technologies to a) Risk Assessment and Susceptibility, b) Diagnosis and Prognosis, c) Pharmacogenomics and Precision Therapeutics, and d) Emerging and Future Opportunities in the field.
- Provides a comprehensive volume written and edited by oncology genomic specialists for oncology health providers
- Includes succinct commentary and key learning points that will assist providers with their local needs for implementation of genomic and personalized medicine into practice
- Presents an up-to-date overview on major opportunities for genomic and personalized medicine in practice
- Covers case studies that highlight the practical use of genomics in the management of patients
Medical students, life sciences and engineering graduate students, advanced undergraduate students, and residents and fellows working with any aspect of genomic research in the life sciences and/or medicine; educators, and translational scientists
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Preface
- Chapter 1. Introduction and overview of cancer precision medicine
- Abstract
- Background
- Opportunities and challenges in precision oncology
- Summary
- References
- Chapter 2. From data to knowledge: an introduction to biomedical informatics
- Abstract
- Introduction
- A primer on the role of biomedical informatics in the era of precision approaches to research, healthcare delivery, and population health
- A framework for selecting, understanding, and assessing biomedical informatics methods
- The relationship between problem solving and methods selection
- Conclusion
- Glossary and abbreviations
- References
- Chapter 3. The functional genome: epigenetics and epigenomics
- Abstract
- Introduction
- The composition of the epigenome
- Histone modifications
- Epigenetic mechanisms of disease
- Epigenetic responses to the environment
- Heritability of the epigenome
- Genome-wide observation of the epigenome
- References
- Chapter 4. Clinical decision support and molecular tumor boards
- Abstract
- Introduction
- Assembling the right team
- Patient and test selection
- Generating clinical recommendations
- Areas for improvement and concluding remarks
- References
- Chapter 5. Family health history and health risk assessment in oncology
- Abstract
- Introduction
- In the beginning
- Why family health history is central to HRAs
- An implementation crisis
- Will providers use it?
- Will the patients use it?
- What about patient-entered data?
- Does it make a difference?
- Conclusion
- References
- Chapter 6. Lymphomas: molecular subsets and advances in therapeutics
- Abstract
- Introduction
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Burkitt lymphoma
- Mantle cell lymphoma
- Leveraging genomics for precision medicine in lymphoma clinical care
- Summary
- References
- Chapter 7. Precision medicine in myeloid neoplasms/acute leukemias
- Abstract
- Introduction
- Spectrum of disease(s)
- Approach to prognosis and treatment recommendations in acute myeloid leukemia
- Summary
- References
- Chapter 8. Lung cancer
- Abstract
- Introduction
- Lung cancer risk and screening
- Diagnosis and molecular characteristics
- Early stage disease
- Genetic testing in metastatic disease
- EGFR mutations
- Squamous cell carcinoma and small-cell lung cancer
- Immunotherapy
- Future directions
- Metastatic disease
- Conclusion
- References
- Chapter 9. Breast cancer
- Abstract
- Introduction
- Estrogen receptor
- Cyclin-dependent kinase, phosphatidylinositol 3-kinase, and mammalian target of rapamycin
- HER2/neu
- Poly(ADP-ribose) polymerase inhibitors
- Immunotherapy
- Conclusion
- References
- Chapter 10. Epithelial ovarian cancer
- Abstract
- Inherited syndromes
- Histologic origins of ovarian cancer
- Genetic hallmarks of ovarian cancer
- Genetic events contributing to ovarian cancer metastasis
- Role of immune responses
- Angiogenesis
- Summary
- References
- Chapter 11. Endometrial cancer
- Abstract
- The Bokhman classification of endometrial cancers
- The Cancer Genome Atlas
- The proactive molecular risk classifier for endometrial cancer (ProMisE) algorithm
- Targetable alterations
- References
- Chapter 12. Colorectal cancer
- Abstract
- Introduction
- Colorectal cancer genetics
- Diagnosis and prognosis of colorectal cancer
- Precision therapeutics for colorectal cancer
- Novel and emerging therapeutics and future opportunities
- Conclusions
- Disclosures
- References
- Chapter 13. Hepatic and bile duct cancers
- Abstract
- Introduction
- Epidemiology
- Genomic alterations
- Integrative molecular classification
- Clinical applications of genomics
- Conclusion
- References
- Chapter 14. Biomarker-directed therapy for pancreatic cancer
- Abstract
- Introduction
- Pancreatic cancers harbor actionable mutations
- FDA-approved, biomarker-based therapies for pancreatic cancer
- Additional promising targets
- Elusive drivers: KRAS, TP53, CDKN2A/2B, and SMAD4
- Future considerations
- Concluding remarks
- References
- Chapter 15. Esophageal and gastric cancer
- Abstract
- Introduction
- Epidemiology and risk factors
- Current classification
- Molecularly targeted therapies in advanced disease
- Immunotherapy in esophageal and gastric cancers
- Key barriers to genomic medicine in esophageal and gastric cancers
- Conclusion and future directions
- References
- Chapter 16. Prostate Cancer
- Abstract
- Introduction
- Precision prostate cancer screening
- Management of localized prostate cancer
- Precision oncology advances in metastatic prostate cancer
- Challenges
- Conclusions
- References
- Chapter 17. Genomics and precision medicine: kidney cancer
- Abstract
- Introduction
- Genomic and molecular profiling of renal cell carcinoma subtypes
- Prognostic implications of molecular markers
- Predictive biomarkers and targeted therapeutics
- Conclusion
- References
- Chapter 18. Head and neck squamous cell carcinoma
- Abstract
- Predisposition
- Screening
- Diagnosis
- Prognosis
- Pharmacogenomics
- Monitoring
- Novel and emerging therapeutics
- Surgery
- Radiation therapy
- Targeted therapies
- Conclusion
- References
- Chapter 19. Melanoma
- Abstract
- Introduction
- Melanoma progression
- Genetics of melanoma
- Clinical applications of genomics in melanoma
- Conclusion
- References
- Chapter 20. Precision cancer immunotherapy
- Abstract
- Introduction
- Immune effector cells, recognition of cancer cells as “foreign” and the cancer microenvironment
- T-cell immunotherapy approaches in cancer
- Prediction of response to immune checkpoint inhibitors and other immunotherapy agents
- Summary
- References
- Index
- No. of pages: 378
- Language: English
- Edition: 3
- Published: April 9, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780128006849
- eBook ISBN: 9780128006535
GG
Geoffrey S. Ginsburg
Dr. Ginsburg is the founding Director of the Center for Applied Genomics & Precision Medicine in the Duke Institute for Genome Sciences & Policy. He is also Professor of Medicine and of Pathology at Duke University Medical Center, Professor of Biomedical Engineering at Duke Pratt School of Engineering, and Co-Director of the Duke Translational Medicine Institute.
Affiliations and expertise
Chief Medical and Scientific Officer, All of Us Research Program, National Institutes of Health, Bethesda, Maryland, USAHW
Huntington F Willard
Huntington Willard is on the faculty of the Department of Human Genetics at the University of Chicago. Prior to this appointment, Willard was the President and Director of the Marine Biological Laboratory and Professor of Human Genetics at the University of Chicago. He was previously on the faculty at Duke University, where he was founding director of the university-wide Duke Institute for Genome Sciences & Policy from 2003 to 2014, the Nanaline H. Duke Professor of Genome Sciences, and the Arts & Sciences Professor of Biology & Genome Sciences.
Affiliations and expertise
Chief Scientific Officer, Genome Medical, Inc., South San Francisco, CA, USAJS
John Strickler
John Strickler is Associate Professor in the Department of Medicine, Division of Medical Oncology at Duke University Medical Center, Durham, NC, USA.
Affiliations and expertise
Associate Professor, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USAMM
Matthew Stuart McKinney
Matthew Stuart McKinney is Assistant Professor of Medicine in the Department of Medicine, Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.
Affiliations and expertise
Assistant Professor of Medicine, Department of Medicine, Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USARead Genomic and Precision Medicine on ScienceDirect